$CURR has already demonstrated that sales and revenue growth are on an ascending curve and as reported for the company's 3rd quarter results. The upcoming year end financials and then the first quarter results after that should be showing increasing momentum based on the initial success of the the products, marketing programs and growing media exposure.
Third Quarter 2022 Results With Strong Sequential and Year Over Year Revenue Increases and Continued High Margins
https://www.accesswire.com/727677/CURE-Pharma...gh-Margins